

Myung Ah Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2971430/publications.pdf>

Version: 2024-02-01

63
papers

1,406
citations

394421

19
h-index

361022

35
g-index

67
all docs

67
docs citations

67
times ranked

2625
citing authors

#	ARTICLE	IF	CITATIONS
1	A structural equation modeling approach to understanding physical function of terminal cancer patients. <i>Supportive Care in Cancer</i> , 2022, 30, 1149-1158.	2.2	0
2	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	3.9	39
3	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS621-TPS621.	1.6	0
4	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS490-TPS490.	1.6	2
5	Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma. <i>Chonnam Medical Journal</i> , 2022, 58, 29.	0.9	2
6	Early-Onset Myasthenia Gravis Following COVID-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, e50.	2.5	25
7	Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. <i>Biomedicines</i> , 2022, 10, 1289.	3.2	6
8	Case 2: A 66-Year-Old Man With Chronic Watery Diarrhea. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	0
9	Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4019-4019.	1.6	10
10	Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4096-4096.	1.6	1
11	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. <i>Cancers</i> , 2021, 13, 331.	3.7	4
12	Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. <i>BMC Cancer</i> , 2021, 21, 77.	2.6	31
13	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. <i>Current Oncology</i> , 2021, 28, 1652-1662.	2.2	4
14	The development and validation of a predictive model for recurrence in rectal cancer based on radiological and clinicopathological data. <i>European Radiology</i> , 2021, 31, 8586-8596.	4.5	4
15	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4161-TPS4161.	1.6	4
16	Current status of cancer immunotherapy with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 326-331.	0.3	1
17	Application of manual aspiration thrombectomy in the treatment of deep vein thrombosis in cancer patients: Descriptive retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0255539.	2.5	0
18	Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 25-31.	3.0	5

#	ARTICLE	IF	CITATIONS
19	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 1176.	2.6	7
20	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32
21	Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. <i>PLoS ONE</i> , 2020, 15, e0240318.	2.5	0
22	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32
23	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62.	2.8	34
24	Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 408-420.	1.7	5
25	Choosing Wisely: The Korean Perspective and Launch of the "Right Decision in Cancer Care"™ Initiative. <i>Cancer Research and Treatment</i> , 2020, 52, 655-660.	3.0	5
26	Capecitabine and cisplatin as a second-line chemotherapy for patients with advanced biliary tract cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 543-543.	1.6	2
27	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	7.1	417
28	Impact of preoperative body compositions on survival following resection of biliary tract cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 794-802.	7.3	29
29	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1100.	2.6	40
30	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019, 10, 6185-6190.	2.5	7
31	β-Catenin expression is associated with cell invasiveness in pancreatic cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 618-625.	1.7	9
32	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1249-1256.	3.0	5
33	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 851-860.	3.0	14
34	Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1021-1030.	2.0	11
35	Withdrawal of life-prolonging medical care and hospice-palliative care. <i>Journal of the Korean Medical Association</i> , 2019, 62, 369.	0.3	4
36	Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 326-334.	7.3	103

#	ARTICLE	IF	CITATIONS
37	Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 239-246.	1.1	18
38	Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?. <i>European Journal of Cancer</i> , 2018, 104, 62-69.	2.8	13
39	Histogram Analysis of Perfusion Parameters from Dynamic Contrast-Enhanced MR Imaging with Tumor Characteristics and Therapeutic Response in Locally Advanced Rectal Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	14
40	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
41	Three Dimensional Mixed-Cell Spheroids Mimic Stroma-Mediated Chemoresistance and Invasive Migration in hepatocellular carcinoma. <i>Neoplasia</i> , 2018, 20, 800-812.	5.3	79
42	Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 283-292.	3.0	4
43	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21539-e21539.	1.6	1
44	Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 452-458.	1.7	15
45	Does the Gadoteric Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with ¹⁸ F-FDG PET/CT. <i>BioMed Research International</i> , 2016, 2016, 1-6.	1.9	8
46	Clinical significance of isolated biliary candidiasis in patients with unresectable cholangiocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2016, 15, 533-539.	1.3	2
47	Clinical characteristics of young-age onset gastric cancer in Korea. <i>BMC Gastroenterology</i> , 2016, 16, 110.	2.0	20
48	Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy. <i>BMC Cancer</i> , 2016, 16, 207.	2.6	10
49	Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1420-1428.	3.0	6
50	Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. <i>BMC Palliative Care</i> , 2015, 14, 53.	1.8	10
51	Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2015, 66, 50.	0.4	6
52	Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 259-265.	3.0	16
53	A Case of Mixed Adenoneuroendocrine Carcinoma of the Common Bile Duct: Initially Diagnosed as Cholangiocarcinoma. <i>Korean Journal of Pathology</i> , 2014, 48, 445-448.	1.3	12
54	Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02. <i>Radiotherapy and Oncology</i> , 2014, 113, 18-23.	0.6	26

#	ARTICLE	IF	CITATIONS
55	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). <i>Radiotherapy and Oncology</i> , 2014, 110, 150-154.	0.6	21
56	Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 125.	2.6	63
57	Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 235.	3.3	28
58	Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1625-1630.	2.5	7
59	Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution.. <i>Journal of Clinical Oncology</i> , 2012, 30, 365-365.	1.6	0
60	Use of high white blood cell (WBC) count to predict poor survival outcome in gastrointestinal (GI) cancer with thrombotic event.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19614-e19614.	1.6	0
61	Survivin expression and its clinical significance in pancreatic cancer. <i>BMC Cancer</i> , 2005, 5, 127.	2.6	51
62	Gemcitabine and Cisplatin Combination Chemotherapy in Intrahepatic Cholangiocarcinoma as Second-line Treatment: Report of Four Cases. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 547-550.	1.3	19
63	Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 346-350.	2.5	38